Table 3 Effects of combining gefitinib with JAK inhibitor (AZD1480), SRC inhibitor (saracatinib), MEK inhibitor (AZD6244), AKT inhibitor (MK2204) and mTOR inhibitor (RAD001), on the viability of SKOV3 cells
Inhibitor | Inhibitor: Gefitinib | Combination index (CI) | Fold reduction (gefitinib) | ||||
|---|---|---|---|---|---|---|---|
ED50 | ED75 | ED90 | IC50 | IC75 | IC90 | ||
JAK | 1:1 | 0.32 | 0.11 | 0.048 | 16.13 | 117.14 | 1764.86 |
SRC | 1:3 | 0.66 | 0.27 | 0.11 | 1.53 | 3.76 | 9.28 |
MEK | 1:4 | 1.09 | 0.83 | 0.62 | 0.95 | 1.26 | 1.68 |
AKT | 1:2 | 0.32 | 0.35 | 0.59 | 6.92 | 3.51 | 1.77 |
mTOR | 1:1 | 0.1 | 0.22 | 0.48 | 10.16 | 4.6 | 2.06 |